MCM
AVEO

Magnolia Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Magnolia Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$8K – 148
2022
Q3 		$8K Hold
1,000
– – 0.01% 121
2022
Q2 		$7K Hold
1,000
– – 0.01% 121
2022
Q1 		$6K Hold
1,000
– – 0.01% 121
2021
Q4 		$5K Buy
+1,000
New +$6.2K ﹤0.01% 118

Other funds holding AVEO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Magnolia Capital Management's AVEO Position: Q4 2022 in Review

Magnolia Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 1,000 shares — an estimated $8K sold.

Magnolia Capital Management first reported a position in AVEO in Q4 2021 and held it in 4 quarters. The position peaked at $8K in Q3 2022. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

  • Magnolia Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Magnolia Capital Management sold 1,000 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $8K.
  • Magnolia Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2021 and held it in 4 quarters.
  • Magnolia Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $8K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on Magnolia Capital Management's 13F filing for Q4 2022, filed 18 Jan 2023.